Novo Nordisk’s mAb for MACE risk reduction fails in Phase III trial
Novo Nordisk’s monoclonal antibody (mAb) designed to reduce the risk of major adverse cardiovascular events (MACE) in patients…
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation
Novo Nordisk A/S Bagsværd, Denmark, 31 July 2026 – Novo Nordisk today announced headline results from the ZEUS cardiovascular…
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation
Novo Nordisk A/S Bagsværd, Denmark, 31 July 2026 – Novo Nordisk today announced headline results from the ZEUS cardiovascular…
Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026
A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults…
Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease
Novo Nordisk A/S Etavopivat showed a 27% reduction in vaso-occlusive crisis events and ~4-month delay to first vaso-occlusive…
Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease
Novo Nordisk A/S Etavopivat showed a 27% reduction in vaso-occlusive crisis events and ~4-month delay to first vaso-occlusive…
Novo Nordisk to seek oral sickle cell therapy approval after Phase III victory
A Phase III trial of Novo Nordisk’s once-daily tablet has met both co-primary endpoints, reducing vaso-occlusive crises (VOC)…
Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease
Novo Nordisk A/S Etavopivat showed a 27% reduction in vaso-occlusive crisis events and ~4-month delay to first vaso-occlusive…